RBC Europe’s Aimmune Therapeutics AIMT Stock Holding History

RBC Europe’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,000	Closed	-$103K	–	1200
2020 Q3	$103K	Hold	3,000	–	–	0.01%	349
2020 Q2	$50.1K	Buy	+3,000	New	+$50.9K	﹤0.01%	442

RBC Europe's AIMT Position: Q4 2020 in Review

RBC Europe sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 3,000 shares — an estimated $103K sold.

RBC Europe first reported a position in AIMT in Q2 2020 and held it in 2 quarters. The position peaked at $103K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

RBC Europe reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
RBC Europe sold 3,000 Aimmune Therapeutics shares in Q4 2020, an estimated $103K.
RBC Europe first reported a position in Aimmune Therapeutics in Q2 2020 and held it in 2 quarters.
RBC Europe's Aimmune Therapeutics position peaked at $103K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on RBC Europe's 13F filing for Q4 2020, filed 9 Nov 2023.